Physician profile
Marcus Morris
NPI 1447608435
$5,687.23
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,017 · 2022: $2,876 · 2023: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $742.65 | 2021-2023 | Mounjaro, Jardiance, Lyumjev |
| Novo Nordisk INC | $550.11 | 2021-2023 | Ozempic, Wegovy, Rybelsus |
| Corcept Therapeutics | $445.38 | 2021-2023 | Korlym |
| Insulet Corporation | $445.02 | 2021-2023 | Omnipod |
| Antares Pharma, INC. | $372.11 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Abbott Laboratories | $262.14 | 2021-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $255.00 | 2021-2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $251.61 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $221.29 | 2021-2023 | Gvoke Hypopen |
| Mannkind Corporation | $220.42 | 2021-2022 | |
| Abbvie INC. | $210.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.78 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $202.74 | 2021-2023 | Unithroid |
| Medtronic, INC. | $162.24 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Radius Health, INC. | $140.59 | 2021-2023 | Tymlos |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.